TMEM97 and cancer: The goal of our current study was to evaluate if the activity profile of LCL161, a clinically explored but underperforming pro-apoptotic cancer drug candidate, could be enhanced by chemical linkage to a cancer-selective sigma-2 receptor ligand (SW43).